NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS

The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC’s Potential as a Disease Modifying Drug. NeuroSense reported statistically significant results from the 12-month data analysis of the PARADIGM Phase 2b study evaluating PrimeC in people living with Amyotrophic Lateral Sclerosis (ALS).